Jump to content

Pubmed-Mind the Gap: The Realities of Novel Irritable Bowel Syndrome Drug Access in Asian Clinical Practice

Health Reporter

Recommended Posts

J Neurogastroenterol Motil. 2024 Jan 30;30(1):4-6. doi: 10.5056/jnm23183.

Irritable bowel syndrome (IBS) is a widespread gastrointestinal disorder with a global prevalence estimated at 8.8% (8.7-8.9%) in adults, as indicated by literature reviews.1 Regional heterogeneity is notable, ranging from 5.8% in the Middle East and Africa to 17.5% in Latin America, with a higher prevalence in females.1 The overall prevalence of IBS in a recent study in East Asia, including Japan, China, and South Korea, using Rome III criteria was slightly higher than the global prevalence, and male patients comprised 54.9% of the cases.2 IBS is associated with a significant financial burden on healthcare and adversely affects patients’ quality of life.3 With these challenges, there is an urgent need to develop and implement novel IBS drugs. The application of these treatments should consider the unique characteristics of each region.

PMID:38173153 | DOI:10.5056/jnm23183

Download the PDF

Link to comment
Share on other sites

  • Create New...